AR036103A1 - Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento - Google Patents
Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamentoInfo
- Publication number
- AR036103A1 AR036103A1 ARP020102343A ARP020102343A AR036103A1 AR 036103 A1 AR036103 A1 AR 036103A1 AR P020102343 A ARP020102343 A AR P020102343A AR P020102343 A ARP020102343 A AR P020102343A AR 036103 A1 AR036103 A1 AR 036103A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- preparation
- alkoxy
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- -1 cyano, hydroxyl Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Imidazotriazinas que comprenden compuestos de fórmula general (1) en la que: R1 representa arilo C6-10 que está eventualmente sustituido de forma igual o distinta con radicales seleccionados del grupo de halógeno, formilo, carbamoílo, ciano, hidroxilo, trifluormetilo, trifluorometoxi, nitro, alquilo C1-6 o alcoxi C1-6, así como eventualmente con un radical de fórmula -SO2NR5R6, en la que R5 y R6 significan independientemente entre sí hidrógeno o alquilo C1-6; o NR5R6 significan un heterociclilo de 4 a 8 miembros unido a través de un átomo de nitrógeno, eventualmente sustituido de forma igual o distinta con radicales seleccionados del grupo de oxo, halógeno, alquilo C1-6 y acilo C1-6; R2 representa un radical hidrocarburo saturado o parcialmente insaturado C1-10; R3 representa metilo o etilo; A representa O, S o NR7; en la que R7 representa hidrógeno o alquilo C1-6 eventualmente sustituido con alcoxi C1-3; E representa un enlace o alcanodiilo C1-3; R4 representa arilo C6-10 o heteroarilo de 5 a 10 miembros, estando eventualmente sustituidos arilo y heteroarilo de forma igual o distinta con radicales seleccionados del grupo de halógeno, formilo, carboxilo, carbamoílo, -SO3H, aminoslfonilo, ciano, hidroxilo, trifluorometilo, trifluorometoxi, nitro, alquilo C16, alcoxi C1-6, 1,3-dioxapropan-1,3-diilo, alquil C1-6 tio, alquil C1-6 sulfinilo y alquil C1-6 sulfonilo, -NR8R9 y heteroarilo de 5 a 6 miembros o fenilo eventualmente sustituido con metilo; significando R8 y R9 independientemente entre sí hidrógeno, alquilo C1-6 o acilo C1-6; y sus sales, hidratos y/o solvatos, procedimientos para su preparación, y su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades neurodegenerativas, especialmente de la enfermedad de Parkinson.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10130167A DE10130167A1 (de) | 2001-06-22 | 2001-06-22 | Imidazotriazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036103A1 true AR036103A1 (es) | 2004-08-11 |
Family
ID=7689090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102343A AR036103A1 (es) | 2001-06-22 | 2002-06-21 | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6936609B2 (es) |
| EP (1) | EP1404677A1 (es) |
| JP (1) | JP2004534827A (es) |
| AR (1) | AR036103A1 (es) |
| CA (1) | CA2451525A1 (es) |
| DE (1) | DE10130167A1 (es) |
| DO (1) | DOP2002000429A (es) |
| GT (1) | GT200200122A (es) |
| PE (1) | PE20030129A1 (es) |
| SV (1) | SV2003001107A (es) |
| WO (1) | WO2003000693A1 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10230605A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| DE10230604A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US7576080B2 (en) * | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP3443958A1 (en) | 2006-11-22 | 2019-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| NZ580413A (en) * | 2007-03-27 | 2012-11-30 | Omeros Corp | The use of pde7 inhibitors for the treatment of movement disorders |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| DE102007060172A1 (de) | 2007-12-13 | 2009-06-25 | Bayer Healthcare Ag | Triazolotriazine und Triazolopyrazine und ihre Verwendung |
| DE102008035209A1 (de) | 2008-07-29 | 2010-02-04 | Bayer Schering Pharma Aktiengesellschaft | Triazolotriazine und Triazolopyrazine und ihre Verwendung |
| DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
| WO2010027097A1 (en) * | 2008-09-04 | 2010-03-11 | Mitsubishi Tanabe Pharma Corporation | Tri-substituted pyrimidine compounds and their use as pde10 inhibitors |
| EP2342191B1 (en) | 2008-09-10 | 2013-03-20 | Mitsubishi Tanabe Pharma Corporation | Aromatic nitrogen-containing 6-membered ring compounds and their use |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
| BR112012021198B1 (pt) | 2010-02-26 | 2021-12-14 | Mitsubishi Tanabe Pharma Corporation | Compostos de pirazolopirimidina, composições relacionadas e seu uso como inibidores de pde10 |
| WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| KR20130083389A (ko) * | 2010-05-28 | 2013-07-22 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 야누스 키나아제 억제제로서 헤테로사이클릭 화합물 |
| NZ610925A (en) | 2010-11-08 | 2015-10-30 | Omeros Corp | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| WO2012112946A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| UA106692C2 (uk) | 2011-02-23 | 2014-09-25 | Пфайзер Інк. | ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ |
| JP2014231475A (ja) * | 2011-08-25 | 2014-12-11 | 田辺三菱製薬株式会社 | 新規化合物及びそのｐｄｅ１０阻害薬としての使用 |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| AU2014221799B2 (en) | 2013-02-27 | 2017-09-28 | Mochida Pharmaceutical Co., Ltd. | Novel pyrazole derivative |
| MA38559B1 (fr) | 2013-05-02 | 2018-04-30 | Pfizer | Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10 |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| CN111825675B (zh) * | 2019-04-15 | 2023-08-01 | 武汉朗来科技发展有限公司 | Rock抑制剂及其制备方法和用途 |
| IL318817A (en) | 2022-08-18 | 2025-04-01 | Mitodicure Gmbh | Use of a therapeutic agent with PHOSPHODIESTERASE-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exercise intolerance |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1457873A (en) * | 1973-01-04 | 1976-12-08 | Allen & Hanburys Ltd | Imidazotriazines |
| DK109578A (da) | 1977-03-25 | 1978-09-26 | Allen & Hanburys Ltd | Fremgangsmaade til fremstilling af heterocycliske forbindelser |
| CA2309332C (en) | 1997-11-12 | 2002-12-03 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| JP2003510349A (ja) * | 1999-10-07 | 2003-03-18 | ノヴァ−ニューロン インコーポレーテッド | 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物 |
-
2001
- 2001-06-22 DE DE10130167A patent/DE10130167A1/de not_active Withdrawn
-
2002
- 2002-06-10 WO PCT/EP2002/006322 patent/WO2003000693A1/de not_active Ceased
- 2002-06-10 US US10/481,281 patent/US6936609B2/en not_active Expired - Fee Related
- 2002-06-10 JP JP2003507096A patent/JP2004534827A/ja not_active Withdrawn
- 2002-06-10 EP EP02747362A patent/EP1404677A1/de not_active Withdrawn
- 2002-06-10 CA CA002451525A patent/CA2451525A1/en not_active Abandoned
- 2002-06-17 GT GT200200122A patent/GT200200122A/es unknown
- 2002-06-21 PE PE2002000536A patent/PE20030129A1/es not_active Application Discontinuation
- 2002-06-21 SV SV2002001107A patent/SV2003001107A/es not_active Application Discontinuation
- 2002-06-21 DO DO2002000429A patent/DOP2002000429A/es unknown
- 2002-06-21 AR ARP020102343A patent/AR036103A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2451525A1 (en) | 2003-01-03 |
| JP2004534827A (ja) | 2004-11-18 |
| PE20030129A1 (es) | 2003-03-13 |
| US20040249148A1 (en) | 2004-12-09 |
| SV2003001107A (es) | 2003-03-18 |
| EP1404677A1 (de) | 2004-04-07 |
| US6936609B2 (en) | 2005-08-30 |
| DE10130167A1 (de) | 2003-01-02 |
| GT200200122A (es) | 2003-06-05 |
| DOP2002000429A (es) | 2003-10-15 |
| WO2003000693A1 (de) | 2003-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036103A1 (es) | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR064889A1 (es) | Derivados de piridopirimidinas, un metodo para su preparacion, una composicion y un producto farmaceutico que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde-4 | |
| CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR062680A1 (es) | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas | |
| AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos | |
| AR036133A1 (es) | Pirazinas, formulacion farmaceutica, usos de estos compuestos para la manufactura de medicamentos, procesos para la preparacion de estos compuestos, y compuestos intermediarios | |
| UY28333A1 (es) | Inhibidores de caspasa y sus usos. | |
| ECSP055636A (es) | Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa | |
| AR040400A1 (es) | Tratamiento de enfermedades mediadas por quimiocinas | |
| AR063680A1 (es) | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. | |
| AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| AR038401A1 (es) | Derivados de indazol substituidos como agentes terapeuticos | |
| PE20050141A1 (es) | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA | |
| TW200508207A (en) | New benzimidazole derivatives | |
| AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
| AR059076A1 (es) | Tiofenil y pirrolil azepinas como ligandos del receptor 5-ht2c de serotonina y usos de las mismas | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| BRPI0607600A2 (pt) | derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina | |
| AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |